• Latest Posts

A Year to Remember: The Biggest European Biotech News in 2020

Why are Some European Biotechs Going Public Without an IPO?

Interview 26 May 2021

Immuno-Oncology: From Science Fiction to the Mainstream

Immatics Partners GSK in Deal Worth €1B to Develop Cancer Therapies

Expert Advice 7 Sep 2019

Why Being in a New Field From the Start Can Pay Off in the Long Run

Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies

ADVERTISEMENT

Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials

Money, Money, Money! Europe’s Best-Funded Biotechs in 2018

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

German Pharma Enters the Clinic with Solid Tumor Treatment

German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers

Infographics 13 Feb 2017

Infographic: What’s in Europe’s Immuno-oncology Pipeline?

ADVERTISEMENT